| Name | Title | Contact Details |
|---|---|---|
Joann Nestor |
General Counsel | Profile |
The Counseling Service of Addison County (CSAC) is a local community mental health center located in Middlebury, Vermont. Since 1959, CSAC has been an integral part of the Addison County community. The Counseling Service offers a wide range of professional mental health and developmental services designed to meet the needs of those seeking help. We are able to provide a multi-disciplinary approach that draws on the expertise of our staff, which includes persons trained in developmental services, substance abuse treatment, psychiatry, psychology, mental health counseling, social work, family therapy, and child therapy. Our goal is to help people live more productive lives in their communities. The following Mission Statement and Values were adopted by the CSAC Board of Directors at their October 9th, 1997 Board meeting. The Mission Statement and Values are the result of several staff and community meetings, where input was gathered. The Counseling Service of Addison County is committed to promoting stable and safe communities by helping people live emotionally healthy and satisfying lives. We strive to provide the best mental health, substance abuse, and developmental services to improve the quality of life for all community members. We work collaboratively with community organizations to help individuals and families achieve maximum wellness.
MicroMRI is a Langhorne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Contact one of our Dental365 offices near you for the best dental care in NY, Connecticut, NJ, Massachusetts & Rhode Island.
New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and ProHEALTH as manager—New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.